TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Can Bristol-Myers Squibb Heal Your Portfolio? Bud Labitan submitsBristol-Myers Squibb Company (BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis. The Company’s products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in eight foreign countries. In September 2009, BMS acquired Medarex, Inc., and in December 2009, it divested the Mead Johnson Nutrition Company (MJN).Last Price: $23.5552 Week High: $27.0752 Week Low: $19.12 Does BMY make for an intelligent investment or intelligent speculation today?Complete Story » seekingalpha.com |
Genzyme Ekes Out Profit, Gives Weak View Genzyme posted a $23,000 profit in the second quarter after production problems hit its two biggest-selling drugs. online.wsj.com |
Rubicon Technology Q2 2010 Earnings Call Transcript Rubicon Technology Inc. (RBCN)Q2 2010 Earnings CallAugust 5, 2010 05:00 pm ETComplete Story » seekingalpha.com |
BioClinica Responds to Shareholder Letter [Business Wire] - BioClinicaâ„¢, Inc. , a global provider of clinical trial management services, has issued the following statement: us.rd.yahoo.com |
Levetown & Jenkins, LLP Announces an Investigation of the Acquisition of Clarient, Inc. by GE Healthcare, a unit of General Electric Company [Business Wire] - Levetown & Jenkins, LLP is conducting an investigation into alleged breaches of fiduciary duties and violations of state law by Clarient, Inc. and its Board of Directors in conjunction with the proposed buyout and acquisition of Clarient by GE Healthcare, a unit of General Electric Company . us.rd.yahoo.com |